Næste

Automatisk afspilning

Long-term trial supports CD19-targeted CAR T cells for relapsed/refractory CLL

2 Visninger • 07/14/23
Del
Indlejre
administrator
administrator
Abonnenter
0

In this episode, Mark Geyer and colleagues demonstrate that second-generation CD19-targeted CAR T cell therapy following conditioning chemotherapy is tolerated in patients with relapsed/refractory CLL and can result in complete remission in a subset of patients…

Vis mere
0 Kommentarer sort Sorter efter
Facebook kommentarer

Næste

Automatisk afspilning